



National Mpox Situation Report

1 Summary

Total Cases	New Last 24h	Number of Deaths	Case Fatality Rate (%)
7,937	0	50	0.63

Key Points:

- Epidemic remains active.** To date 82% (120/146) of districts reported atleast one case since the beginning of the outbreak and 22%(32/146) reporting new cases in the past 21 days.
- Overall decline.** There has been an overall decline in the weekly incident cases reported
- Flattening curve.** There is an apparent flattening of the curve as indicated in the cumulative curve in **figure 2.7** over the last 30 days.
- High-risk mortality observed.** Cumaulatively 48 deaths have occurred among confirmed cases, half (47.9%) of whom were **co-infected with HIV**.
- Young adults are disproportionately affected.** Attack rates are highest among females aged 24–29 (AR: 0.9/100,000). Among males, the most affected agegroup is 35-39 (AR: 1.5/100,000).

Weekly and Cumulative Confirmed Mpox Cases¹

Year	Epi Week	Weekly Confirmed Cases	Cumulative Confirmed Cases	Percent Change (%)
2025	26	233	7231	3.33
2025	27	173	7404	2.39
2025	28	108	7512	1.46
2025	29	74	7586	0.99
2025	30	124	7710	1.63
2025	31	83	7793	1.08
2025	32	71	7864	0.91
2025	33	10	7874	0.13
2025	34	31	7905	0.39
2025	35	32	7937	0.40

¹ This is data for the last 10 Epiweeks. % Week-on-Week Change

2 Surveillance and Epidemiology

2.1 Summary Table of Incident Cases by Age and Sex

Cases by Age Group and Gender						
Distribution across demographics						
Age Group	Total Cases	% of Cases ¹	Males	% of All Males ²	Females	% of All Females ²
0-4	351	4.7%	202	4.7%	149	4.7%
5-9	323	4.3%	182	4.2%	141	4.4%
10-14	224	3.0%	122	2.8%	102	3.2%
15-19	698	9.3%	330	7.6%	368	11.6%
20-24	1,253	16.7%	559	12.9%	694	21.8%
25-29	1,572	20.9%	864	19.9%	708	22.2%
30-34	1,177	15.6%	720	16.6%	457	14.4%
35-39	901	12.0%	609	14.0%	292	9.2%
40-44	515	6.8%	363	8.4%	152	4.8%
45-49	307	4.1%	228	5.3%	79	2.5%
50+	203	2.7%	161	3.7%	42	1.3%
sum	—	7,524 ³	4,340	100.0%	3,184	100.0%


¹ Percentage of all cases within each age group
² Percentage of all cases within each gender category
³ Total cases less due to some missing age information

2.2 Summary Table of Incident Cases by the Top 10 Districts



Top 10 Districts Summary					
District	Total Cases	Total Deaths	Cases Last Epiweek	Deaths Last Epiweek	% Change in Cases ¹
Kampala District	2,715	16	1	0	-75.0%
Wakiso District	955	8	3	0	50.0%
Mbarara City	693	5	0	0	-100.0%
Masaka City	346	3	0	0	-100.0%
Mukono District	287	2	1	0	NA
Hoima City	209	2	2	0	NA
Lyantonde District	143	0	0	0	NA
Nakasongola District	128	1	0	0	NA
Luwero District	112	0	0	0	NA
Mubende District	109	0	0	0	-100.0%

¹ The percentage change in cases is calculated by comparing the number of cases in the most recent epidemiological week to the previous epidemiological week.


2.3 Proportion of Affected Districts



2.4 Overall Distribution of Incident Cases by Time




2.5 Epicurves of the Top 10 Districts




2.6 Overall Distribution of Incident Cases by Time


2.7 Weekly Cumulative Cases




2.8 Overall Distribution of Incident Cases by Age and Sex




2.9 Overall Distribution of Deaths by Place and Sex - Age



2.10 Distribution of Deaths by HIV Status




2.11 Overall Attack Rates by Age





2.12 Distribution of Incident Cases by Place(Absolute Numbers)



2.13 Attack Rates per 100K Population by Place



2.14 Attack Rates per 100K Population by Place and Top 10 Districts





MPOX CASE DEFINITION

COMMUNITY CASE DEFINITION

- An illness with signs of skin rash, fever, headache, muscle aches, back pain, and body weakness.

SUSPECTED CASE

- Any person with skin rash on any part of the body not explained by any locally relevant common cause of papular or vesicular rash, mucosal lesions or swollen lymph nodes with acute onset of fever ($>38.5^{\circ}\text{C}$), headache, myalgia (muscle pain/body ache), back pain, profound weakness, or fatigue.



PROBABLE CASE

- A suspect case with history of contact to probable or confirmed Mpxox case 21 days before the onset of signs or symptoms

OR

- Has an epidemiological link to a probable or confirmed case of Mpxox in the 21 days before symptom onset including multiple and/or casual sexual partners in the 21 days before symptom onset; has a positive test result for orthopoxviral infection (e.g., OPXV-specific PCR without MPXV-specific PCR or sequencing)

CONFIRMED CASE

- A person with laboratory confirmed MPXV infection by detection of unique sequences of Viral DNA by real-time polymerase chain reaction (RT-PCR) and/or sequencing

Contact Us

Twitter: @MinofHealthUG
Website: <https://health.go.ug/>
Talk to Us: 0800-100-066
Write to Us: helpdesk@health.go.ug

